The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAs life sciences companies refine their portfolios through strategic M&A, Jefferies has resumed coverage of Agilent Technologies with a 'Hold' rating and a $135 price target. The firm anticipates modest revenue growth supported by the company's recent acquisition of Biocare, which is expected to drive long-term improvements in operating margins. However, analysts cautioned that the integration could lead to a slight dilution of earnings per share (EPS) in the immediate future.
This neutral stance arrives as the broader healthcare equipment sector navigates mixed demand signals, with peers like Thermo Fisher Scientific reporting stabilized industrial demand in recent quarterly filings. Jefferies' price target suggests limited upside from recent trading levels, reflecting a disciplined valuation approach toward the laboratory and diagnostics market recovery.
Per market data, Agilent (A) closed at $131.14 on July 7, 2026, having traded between a low of $129.99 and a high of $132.79 during that session. Investors are now looking toward upcoming catalysts, including the U.S. ISM Services PMI data, to gauge the broader capital expenditure environment and the company's ability to execute on its margin expansion goals following the Biocare deal.